Hinova is a global and in the advanced development stage biopharmaceutical organization focused on creating groundbreaking deuterated and hybrid degraders for tumors and metabolic disorders. The firm is pursuing 4 programs in the advanced stage: HC-1119, a deuterated variant of enzalutamide, designed for treating men with mCRPC; HP501, an URAT1 inhibitor for the management of hyperuricemia/gout; HP558, a pioneering CD44v6 inhibitor for the treatment of esophageal cancer; and HP518, an oral AR degrader, offering the potential to address drug resistance in prostate cancer due to AR variation.